The road to resistance: EGFR mutation and cetuximab

Alberto Bardelli, Pasi A. Jänne

Research output: Contribution to journalArticlepeer-review

Abstract

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

Original languageEnglish
Pages (from-to)199-200
Number of pages2
JournalNature Medicine
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2012

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'The road to resistance: EGFR mutation and cetuximab'. Together they form a unique fingerprint.

Cite this